CSC'S DVC ENTERS TRIAL FOR EQUINE ENCEPHALITIS VACCINE
Computer Sciences has announced that DVC LLC, a CSC company, has entered into a Phase I clinical trial for its Venezuelan equine encephalitis (VEE) vaccine candidate V3526.
The trial will evaluate the safety, tolerability and immunogenicity of the vaccine candidate in healthy volunteers between the ages of 18 and 40. Clinical testing is underway and will continue into 2006 at Northwest Kinetics in Tacoma, Wash. Contract research services for the single center, open-label study will be provided by the Covalent Group, headquartered in Wayne, Penn.
VEE is a mosquito-borne viral disease that causes encephalitis in horses and humans. It is an important public health problem in Central and South America.